INNOVADERM CRO IS NOW INDERO.

Innovaderm Research, a dual-focus CRO, Appoints Jeff Smith as New CEO

Indero

Indero

Team of Experts

Author picture

Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients.

Jeff brings nearly 30 years of experience in the pharmaceutical and CRO industry, most recently as CEO of another therapeutically focused CRO, where he has distinguished himself through his exceptional leadership, strategic vision, and ability to innovate. His expertise spans global operations, growth management, and fostering a collaborative and high-performing corporate culture. Jeff’s strengths in value creation, partner management, and CRO operations have consistently driven success in his previous roles.

Jeff is well-equipped to lead Innovaderm into its next phase of growth and innovation. Innovaderm is excited to add therapeutic expertise in rheumatology in addition to our world class dermatology research services, further expanding our capabilities and dedication to advancing medical knowledge and new therapies as a dual-focused CRO. Mr. Smith’s proven track record in organizational expansion and achieving meaningful and impactful results will be invaluable in driving these efforts forward.

“I am truly honored to join Innovaderm as CEO and collaborate with such a dedicated and talented team.  Together, we are poised to work together with our sponsors to drive innovation in clinical research, making meaningful advancements in dermatology and rheumatology that will directly benefit patients and improve their quality of life.” Jeff Smith

Dr. Bissonnette, the founder of Innovaderm, remains as Executive Chairman, ensuring the CRO’s continuity and stability. His ongoing leadership will continue to guide Innovaderm’s mission to advance clinical research and improve patient outcomes. “I am confident Jeff Smith’s leadership will drive Innovaderm to new heights.” said Dr. Robert Bissonnette.

For more information about our dermatology and rheumatology services please visit:
https://innovaderm.com

Innovaderm Research Inc.

Innovaderm Research Inc. is a specialized CRO with a dual focus on dermatology and rheumatology. We assist biopharmaceutical sponsors in initiating and completing clinical trials. With over 25 years of globally recognized expertise in dermatology and clinical operations, an extensive and continually expanding network of clinicians and sites, and a dedicated research clinic, Innovaderm offers a highly informed, focused, and comprehensive approach to addressing niche clinical needs in dermatology and rheumatology.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.